Benefit of interferon β-1a on MSFC progression in secondary progressive MS

Neurology

Volumn 59, Issue 5, 2002, Pages 679-687

  Cohen, J A ^a   Cutter, G R ^b   Fischer, J S ^a   Goodman, A D ^c   Heidenreich, F R ^d   Kooijmans, M F ^e   Sandrock, A W ^e   Rudick, R A ^a   Simon, J H ^f   Simonian, N A ^e   Tsao, E C ^e   Whitaker, J N ^g  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e BIOGEN   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g The University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; NEUTRALIZING ANTIBODY; PLACEBO;

ADULT; ARTICLE; CHILL; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; MOBILIZATION; MULTIPLE SCLEROSIS; PHYSICAL DISABILITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; TREATMENT OUTCOME; VOMITING;

EID: 0037056364     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.59.5.679     Document Type: Article

References (40)

1. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
2. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. Ann Neurol 1998;43:79-87.
3. Fischer JA, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon β-1a in relapsing multiple sclerosis. Ann Neurol 2000;48:885-892.
4. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904.
5. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497.
6. Goodkin DE, the North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial. Neurology 2000;54:2352. Abstract.
7. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Clinical results. Neurology 2001;56: 1496-1504.
8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
9. Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler 1995;1:37-47.
10. Rudick R, Antel J, Confavreux C, et al. Clinical outcomes assessment in multiple sclerosis. Ann Neurol 1996;40: 469-479.
11. Rudick R, Antel J, Confavreux C, et al. Recommendations from the National Multiple Sclerosis Society clinical outcomes assessment task force. Ann Neurol 1997;42:379-382.
12. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122:871-882.
13. Fischer JS, Rudick RA, Cutter GR, Reingold SC, the National MS Society Clinical Outcomes Assessment Task Force. The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler 1999;5:244-250.
14. Fischer JS, Jak AJ, Knicker JE, Rudick RA, Cutter G. Administration and scoring manual for the multiple sclerosis functional composite (MSFC). New York: Demos, 1999.
15. Cohen JA, Fischer JS, Bolibrush DM, et al. Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology 2000;54:802-806.
16. Cohen JA, Cutter GR, Fischer JS, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 2001;58:961-967.
17. Kalkers NF, de Groot V, Lazeron RHC, et al. MS functional composite, relation to disease phenotype and disability strata. Neurology 2000;54:1233-1239.
18. Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS. Clinical significance of the Multiple Sclerosis Functional Composite. Relationship to patient-reported quality of life. Arch Neurol 2000;57:1319-1324.
19. Hoogervorst ELJ, van Winsen LML, Eikelenboom MJ, Kalkers NF, Uitdehaag BMJ, Polman CH. Comparisons of patient self-report, neurologic examination, and functional impairment in MS. Neurology 2001;56:934-937.
20. Fisher E, Rudick RA, Cutter G, et al. Relationship between brain atrophy and disability: an 8-year followup study of multiple sclerosis patients. Mult Scler 2000;6:373-377.
21. Kalkers NF, Bergers L, de Groot V, et al. Concurrent validity of the MS Functional Composite using MRI as a biological disease marker. Neurology 2001;56:215-219.
22. Rudick RA, Cutter G, Baier M, et al. Use of the multiple sclerosis functional composite to predict disability in relapsing MS. Neurology 2001;56:1324-1330.
23. Poser C, Paty D, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
24. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911.
25. Taves DR. Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther 1974; 15:443-453.
26. Simonian N, Goodman A, Guarnaccia J, et al. An open-label tolerability study of interferon beta-1a in combination with steroids and pentoxyfylline in patients with moderate to severe multiple sclerosis. Ann Neurol 1998;44:504. Abstract.
27. Ritvo PG, Fischer JF, Miller DM, Andrews H, Paty D, LaRocca NG. Multiple Sclerosis Quality of Life Inventory: a user's manual. New York: National Multiple Sclerosis Society, 1997.
28. Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult Scler 1999;5:251-259.
29. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 1998;50:1266-1272.
30. Rudick RA, Miller D, Clough JD, Gragg LA, Farmer RG. Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol 1992;49:1237-1242.
31. Solari A, Filippini G, Gasco P, et al. Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology 1999;52:57-62.
32. Freeman JA, Langdon DW, Hobart JC, Thompson AJ. Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community? Neurology 1999;52:50-56.
33. Nortvedt MW, Riise T, Myhr KM, Nyland HI. Performance of the SF-36, SF-12, and RAND-36 summary scales in a multiple sclerosis population. Med Care Res Rev 2000;38: 1022-1028.
34. Janardhan V, Bakshi R. Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis. Arch Neurol 2000;57: 1485-1491.
35. Rothwell PM, McDowell Z, Wong CK, Dorman PJ. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. BMJ 1997;314:1580-1583.
36. McFarland HF. Comparative analysis of the outcome of two phase III studies of interferon beta-1b. Neurology 2000;54: 2352. Abstract.
37. Schwid SR, Goodman AD, Apatoff BR, et al. Are quantitative functional measures more sensitive to worsening MS than traditional measures? Neurology 2000;55:1901-1903.
38. Syndulko K, Tourtellotte WW, Baumhefner RW, et al. Neuroperformance evaluation of multiple sclerosis disease progression in a clinical trial: implications for neurological outcomes. J Neurol 1993;7:153-176.
39. Baier ML, Cutter GR, Rudick RA, et al. Performance of a visual function test in a multiple sclerosis cohort. Neurology 2000;54(suppl 3):A214. Abstract.
40. Goodkin DE, Rudick RA, Medendorp SV, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995;37: 30-41.